Management and dosing of warfarin therapy

被引:116
作者
Gage, BF
Fihn, SD
White, RH
机构
[1] Washington Univ, Sch Med, Div Gen Med Sci, St Louis, MO 63110 USA
[2] Univ Washington, Div Gen Internal Med, Seattle, WA 98195 USA
[3] VA Puget Sound Hlth Care Syst, Seattle, WA USA
[4] Univ Calif Davis, Div Gen Med, Sacramento, CA 95817 USA
关键词
D O I
10.1016/S0002-9343(00)00545-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
When initiating warfarin therapy, clinicians should avoid loading doses-that can raise the International Normalized Ratio (INR) excessively; instead, warfarin should be initiated with a 5-mg dose (or 2 to 4 mg in the very elderly). With a 5-mg initial dose, the INR will not rise appreciably in the first 24 hours, except in rare patients who will ultimately require a very small daily dose (0.5 to 2.0 mg). Adjusting a steady-slate warfarin dose depends on the measured INR values and clinical factors: the dose does not need to be adjusted for a single INR that is slightly out of range, and most changes should alter the total weekly dose by 5% to 20%. The INR should be monitored frequently (eg, 2 to 4 times per week) immediately after initiation of warfarin; subsequently, the interval between INR tests can be lengthened gradually (up to a maximum of 4 to 6 weeks) in patients with Stable INR values. Patients who have an elevated INR will need more frequent testing and may also require vitamin K1. For example, a nonbleeding patient with an INR of 9 can be given low-dose vitamin K1 (eg, 2.5 mg phytonadione, by mouth). Patients who have an excessive INR with clinically important bleeding require clotting factors leg, fresh-frozen plasma) as well as vitamin K1. Am J Med. 2000;109:481-488. (C) 2000 by Excerpta Medica, Inc.
引用
收藏
页码:481 / 488
页数:8
相关论文
共 106 条
  • [1] A randomized comparison of a computer-based dosing program with a manual system to monitor oral anticoagulant therapy
    Ageno, W
    Turpie, AGG
    [J]. THROMBOSIS RESEARCH, 1998, 91 (05) : 237 - 240
  • [2] EVALUATION OF A PORTABLE PROTHROMBIN TIME MONITOR FOR HOME-USE BY PATIENTS WHO REQUIRE LONG-TERM ORAL ANTICOAGULANT-THERAPY
    ANDERSON, DR
    HARRISON, L
    HIRSH, J
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1993, 153 (12) : 1441 - 1447
  • [3] Consensus guidelines for coordinated outpatient oral anticoagulation therapy management
    Ansell, JE
    Buttaro, ML
    Thomas, IV
    Knowlton, CH
    Becker, DM
    Bussey, HI
    Corey, R
    Gums, JG
    Hughes, R
    Jacobson, A
    Kirchain, W
    Kuhn, K
    Loken, S
    McCain, J
    Haley, JA
    Oertel, LB
    Thrasher, K
    Triplett, DA
    Whitcomb, H
    Wittkowsky, AK
    Zarus, SA
    [J]. ANNALS OF PHARMACOTHERAPY, 1997, 31 (05) : 604 - 615
  • [4] LONG-TERM PATIENT SELF-MANAGEMENT OF ORAL ANTICOAGULATION
    ANSELL, JE
    PATEL, N
    OSTROVSKY, D
    NOZZOLILLO, E
    PETERSON, AM
    FISH, L
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (20) : 2185 - 2189
  • [5] Determinants of compliance with anticoagulation: A case-control study
    Arnsten, JH
    Gelfand, JM
    Singer, DE
    [J]. AMERICAN JOURNAL OF MEDICINE, 1997, 103 (01) : 11 - 17
  • [6] Optimal intensity of oral anticoagulant therapy after myocardial infarction
    Azar, AJ
    Cannegieter, SC
    Deckers, JW
    Briet, E
    vanBergen, PFMM
    Jonker, JJC
    Rosendaal, FR
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1996, 27 (06) : 1349 - 1355
  • [7] INVESTIGATION OF PATIENTS WITH ABNORMAL RESPONSE TO WARFARIN
    BENTLEY, DP
    BACKHOUSE, G
    HUTCHINGS, A
    HADDON, RL
    SPRAGG, B
    ROUTLEDGE, PA
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 22 (01) : 37 - 41
  • [8] BEYTH RJ, 2000, IN PRESS ANN INTERN
  • [9] BJORNSSON TD, 1978, LANCET, V2, P846
  • [10] Brigden ML, 1998, AM J HEMATOL, V59, P22, DOI 10.1002/(SICI)1096-8652(199809)59:1<22::AID-AJH5>3.3.CO